Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SUGEN
• Treatments: Semaxinib

Criteria

Inclusion Criteria

You may be eligible for this study if you:

• Are at least 18 years old.

• Are HIV-positive.

• Have KS with at least 5 skin lesions.

• Have been in stable condition for at least 6 weeks prior to study entry, if receiving antiretroviral therapy.

• Agree to use effective methods of birth control during the study.

Exclusion Criteria

You will not be eligible for this study if you:

• Have had surgery within 4 weeks of study entry.

• Have taken certain medications, including therapy for KS, within 3 weeks prior to study entry.

• Have pulmonary KS (KS in your lungs).

• Have certain serious medical conditions, including liver or kidney problems, certain infections, and certain cancers.

• Are allergic to Cremophor.

• Have not recovered from previous cancer treatment (chemotherapy, radiotherapy, or immunotherapy).

• Are pregnant.